advertisement

Good Medicine.(Biotech industry.)

Kiplinger's Value Added Web Column, May, 2005

Byline: Steven Goldberg, Kiplinger Washington Editors Biotech is beginning to realize its potential -- for investors as well as patients. Meanwhile, pharmaceutical companies are continuing to struggle, although they will probably begin to see some improvement starting next year. Those are the views of Kris Jenner, manager of T.

Rowe Price Health Sciences (PRHSX), probably the best health care sector fund available now that Vanguard Health Care is closed to new investors. The fund's returns place it in the top 30% among health care funds over the past five years, yet it has exhibited only about the same volatility as the S&P 500 -- rare for a sector fund. Fully 45% of the fund is in biotech. Jenner likes biotech companies because they're smaller...

Premium Content Partnership | HighBeam Research provides an in-depth online archive library of reference works. HighBeam Research

 

BNET TalkbackShare your ideas and expertise on this topic

Please add your comment:

  1. You are currently: a Guest |
  2.  

Basic HTML tags that work in comments are: bold (<b></b>), italic (<i></i>), underline (<u></u>), and hyperlink (<a href></a)

advertisement
advertisement
  • Click Here
  • Click Here
  • Click Here